Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Dr. Soumya Chatterjee, MD, MS, FRCP(UK), FACP, FACR is a Staff Physician in the Orthopedic and Rheumatologic Institute at the Cleveland Clinic. He is also an Associate Professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He is board-certified in rheumatology and is a fellow of the American College of Physicians, the American College of Rheumatology, and the Royal College of Physicians of the United Kingdom.
Dr. Chatterjee joined the medical staff in the Department of Rheumatic and Immunologic Diseases at the Cleveland Clinic in 2004, following a faculty appointment at Wayne State University, Detroit, Michigan. Dr. Chatterjee brings with him extensive clinical experience in rheumatology and internal medicine. After his undergraduate and postgraduate medical training in India, he had further postgraduate training in internal medicine in the United Kingdom. His former training in rheumatology was also in the United Kingdom, where he completed 3 years of rheumatology fellowship training after obtaining Membership of the Royal College of Physicians in 1993. His training in the US was at Wayne State University, Detroit, Michigan where he completed an internal medicine residency, chief residency in internal medicine, and then his second fellowship in rheumatology. In 2003, he also obtained a Master of Science degree in Clinical Research Design and Statistical Analysis from the School of Public Health of the University of Michigan.
Dr. Chatterjee is a general rheumatologist who sees patients with complex, multisystem rheumatologic conditions. He takes care of patients with rheumatoid arthritis, lupus, and myositis. His special interest is in scleroderma (systemic sclerosis). In 2005, the Cleveland Clinic Scleroderma Program was established under his leadership, and he has been involved in several research projects in scleroderma. He also participates in a weekly rheumatology-pulmonary combined clinic where patients with various autoimmune rheumatologic diseases (such as scleroderma, lupus, polymyositis, rheumatoid arthritis, etc.) who have pulmonary complications (interstitial lung disease or pulmonary hypertension) are evaluated and managed, in conjunction with two pulmonologists.
Dr. Chatterjee enjoys and spends considerable time teaching and mentoring internal medicine residents and rheumatology fellows. He was awarded 'Teacher of the Year' by the Cleveland Clinic rheumatology fellows in 2006 and 2010.
Scleroderma, rheumatoid arthritis, lupus, myositis
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 6/9/2015, Dr. Chatterjee has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.